Minirin Melt (Desmopressin)

Desmopressin, the active ingredient in Minirin Melt, is a vasopressin analog presented as an oral melt for oral use. It is employed to treat central diabetes insipidus and nocturnal enuresis by reducing excessive urine production.

GNH USA supplies Minirin Melt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for regulated medicines across multiple regions. Its network includes distribution hubs in Europe, Asia and Africa.

Desmopressin acts on the antidiuretic hormone pathway to correct water balance disorders, making it useful in specific clinical settings.

- Central diabetes insipidus: reduces polyuria and thirst by increasing water reabsorption in the kidneys. - Nocturnal enuresis (bedwetting): lowers nighttime urine output, helping children and adults achieve dry nights. - Primary nocturnal enuresis in children: improves bladder control during sleep by concentrating urine.

Desmopressin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional upset stomach. - Abdominal discomfort: mild cramps or pain. - Mild hyponatremia: slight reduction in serum sodium without symptoms. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Severe hyponatremia: marked sodium loss that can lead to confusion or seizures. - Water intoxication: excessive fluid retention causing edema and pulmonary congestion. - Seizures: neurological events linked to profound hyponatremia. - Allergic reactions: rash, itching or swelling of the face. - Blood pressure changes: hypotension or hypertension in susceptible individuals.

When prescribing Desmopressin, clinicians should observe several precautionary measures to minimise risk. - Monitor serum sodium: check electrolytes before and during therapy to detect hyponatremia. - Adjust dose in renal impairment: reduced clearance may increase drug exposure. - Limit fluid intake: advise patients to avoid excessive drinking while on treatment. - Use caution in the elderly: age‑related renal changes raise the risk of water retention. - Contraindicated in existing hyponatremia: do not initiate therapy if sodium levels are already low. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Desmopressin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Vasopressin antagonists (e.g., conivaptan): block V2 receptors and negate Desmopressin’s effect. - Loop or thiazide diuretics: increase risk of hyponatremia by enhancing water retention. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may potentiate antidiuretic action and raise sodium loss.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): combined use can predispose to hyponatremia. - Antihypertensive agents: additive blood‑pressure lowering effect may occur. - Alcohol: may increase fluid intake and exacerbate water‑retention risk.